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Abstract 
R loops are transient three-stranded nucleic acid structures that form physiologically during transcription when a nascent RNA 
transcript hybridizes with the DNA template strand, leaving a single strand of displaced nontemplate DNA. However, aberrant 
persistence of R-loops can cause DNA damage by inducing genomic instability. Indeed, evidence has emerged that R-loops might 
represent a key element in the pathogenesis of human diseases, including cancer, neurodegeneration, and motor neuron disorders. 
Mutations in genes directly involved in R-loop biology, such as SETX (senataxin), or unstable DNA expansion eliciting R-loop 
generation, such as C9ORF72 HRE, can cause DNA damage and ultimately result in motor neuron cell death. In this review, we 
discuss current advancements in this field with a specific focus on motor neuron diseases associated with deregulation of R-loop 
structures. These mechanisms can represent novel therapeutic targets for these devastating, incurable diseases. 
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Introduction 
 
The etiopathogenesis of neurodegenerative diseases, such as 
Alzheimer’s disease, Parkinson’s disease, and amyotrophic 
lateral sclerosis (ALS), remains largely unknown, which 
hampers the rational development of effective treatments. 
These disorders have in common the selective loss of a spe- 
cific neuronal subpopulation. In several neurodegenerative 
diseases, this progressive cell death has been related to a 
common neuropathological feature, namely the accumula- 
tion of proteins that aggregate in cells due to their misfolded 
or altered structure [1, 2]. Although a common underlying 
pathological feature of many neurodegenerative diseases is 
the accumulation of protein aggregates, it is not clear whether 
such structures are universally toxic to neurons. Indeed, re- 
cent studies have highlighted the possible role of RNA alter- 
ations in the pathogenesis of these disorders [3]. In particular, 
the defect in the resolution of transcriptional R-loops, a con- 
sequence of abnormal mRNA metabolism, is thought to be 
responsible for DNA damage and genome instability [4–6]. 
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This notion represents a new perspective in the comprehen- 
sion of the pathogenesis of these diseases and may possibly 
open paths to new therapeutic targets. 
R-loops are transient nucleic acid structures composed of 
three strands (mRNA, template DNA strand, and not-template 
DNA strand) that form during the transcriptional process. In 
the course of transcription, dsDNA is unwound, and one 
strand of the DNA double helix is copied into a complemen- 
tary RNA transcript. Within the transcription bubble, the two 
strands of DNA are physically separated, and a transient 8-bp 
RNA/DNA hybrid forms [7]. In most cases, the two DNA 
strands reanneal as the RNA is synthesized along the DNA. 
However, R-loops can develop in particular over DNA re- 
gions characterized by high G density, negative supercoiling, 
and DNA nicks [8] during transcription. The exact mechanism 
of R-loops generation remains unclear. In specific circum- 
stances, the RNA:DNA hybrid could be maintained and ex- 
tended as the polymerase moves forward, leaving the other 
DNA strand unbound. Another mechanism proposed for R- 
loops generation is the thread-back model. In this model, the 
nascent RNA transcript exiting the active site of RNA poly- 
merase can anneal to the template DNA strand before the 
reannealing of the two strands of the DNA duplex, generating 
a RNA:DNA hybrid that is more stable than dsDNAs [9] and 
discarding the non-template, single-stranded DNA [10–12]. 
A number of cellular processes are controlled by the pro- 
grammed formation of R-loops, e.g., Ig class switch recombi- 
nation and termination of transcription [12]. Normally, R-loop 
  
 
 
 
levels are under tight control, and R-loop formation is limited 
by the binding of RNA-binding proteins to the forming RNA, 
reducing its hybridization to the DNA template. In addition, 
R-loops can be actively resolved by the action of RNA/DNA 
helicases and RNase H1 [13, 14]. 
Defects in the mechanisms responsible for the resolution of 
R-loops or the presence of a G-rich sequence in the 
nontemplate DNA that stabilizes R-loops by the formation 
of G-quadruplexes can lead to aberrant and potentially harm- 
ful R-loops; impairment of R-loop levels may induce alter- 
ation of chromatin structure and transcriptional modification, 
DNA double-strand breaks, and consequent cellular damage 
[13, 15, 16]. Indeed, knockdown of RNA splicing and trans- 
port factors is associated with increased R-loop formation and 
consequential DNA damage [17, 18]. 
In recent years, an increasing number of studies [12, 19] 
have highlighted the altered metabolism of R-loops as a pos- 
sible source of genome instability involved in the pathogene- 
sis of a variety of diseases, including cancers and neurodegen- 
erative disorders [20]. 
Currently, the following main mechanisms have been ac- 
knowledged to be responsible for nonphysiological R-loop 
formation in neurodegenerative disorders, depending on the 
genetic defect characterizing the diseases (Table 1): (1) muta- 
tions in genes encoding factors playing a role in the R-loop 
generation and resolution pathways, i.e., senataxin, a RNA/ 
DNA helicase responsible for R-loop resolution at transcrip- 
tion termination sites [22, 32] and (2) the presence of patho- 
genic repeat expansion (Fig. 1). Numerous repeat sequences 
causing neurodegenerative diseases form stable R-loops that 
subsequently contribute to repeat instability [33–36]. For in- 
stance, the CAG/CTG expansion that causes greater than 13 
different diseases, including Huntington’s disease (HD), myo- 
tonic dystrophy type 1 (DM1), and multiple spinocerebellar 
ataxias (SCAs), creates R-loops and promotes genetic insta- 
bility [34]. 
Furthermore, the expansion of the GAA repeats in the 
first FXN gene that causes Friedreich ataxia is thought to 
be capable of promoting R-loop formation and stabilization 
given its G-rich content, resulting in focal DNA breaks [21]. 
Despite the fact that these mutations occur in ubiquitously 
expressed genes, these diseases present primarily neurolog- 
ic deficits and most strikingly motor neuron signs, 
highlighting a particular sensitivity of the nervous system 
and motor neurons to defects in R-loop metabolism and 
genome stability. 
In this work, we intend to present and discuss recent ad- 
vancements in elucidating the role of R-loops in motor neuron 
disorders and their possible therapeutic implications. 
 
 
R-Loops in Motor Neuron Disease 
Amyotrophic Lateral Sclerosis 
 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative 
disease characterized by an adult onset and a fatal outcome 
typically 3 to 5 years after diagnosis. ALS is characterized by 
signs and symptoms due to the degeneration of both upper and 
lower motor neurons located in the brain and in the spinal 
cord, respectively, that clinically leads to progressive muscle 
weakness and paralysis until the end stage with death from 
respiratory failure [37]. 
To date, riluzole and edavarone are the only two approved 
therapies for ALS. However, these agents only modestly slow 
disease progression, and all patient management relies on 
symptomatic therapies [37, 38]. 
Although mutations in different genes with different neu- 
ronal functions cause some ALS cases, most patients exhibit 
sporadic disease and develop the disease through unknown 
mechanisms [39]. Recent findings suggest an involvement 
of R-loops in the pathogenesis of the ALS forms with known 
genetic causes [20, 40]. This association has not been demon- 
strated in sporadic ALS forms without identified genetic 
causes to date. Here, we review the possible associations be- 
tween ALS causative genes and pathological R-loop forma- 
tion. This information could contribute to understanding the 
disease pathogenesis, identifying common pathogenic mech- 
anisms for different types of ALSs, and subsequently reveal- 
ing novel therapeutic targets. 
 
Table 1 Different gene 
mutations/alterations that lead to 
R-loop formation in motor neuron 
diseases 
 
 
Disease Mechanism 
 
 
C9orf72 HRE ALS [21] R-loop stabilization (G4-DNAs) 
ATXN2 repeats expansion ALS [6, 22] Alteration of R-loop resolution 
SETX mutations ALS4 [23], AOA2 [24–27] Altered RNA/DNA helicase function 
TDP-43/FUS mutations ALS [22, 28] Altered RNA binding protein function 
ATNX 2 and SMN sequestration 
SMN mutations SMA [29, 5] Altered splicing, consequential R-loop 
increase 
Altered SETX recruitment 
IGHMBP2 mutations SMARD1 [30, 31] Altered RNA/DNA helicase function 
 
 
  
 
Fig. 1 Role of R-loops in motor 
neuron disease pathogenesis. R- 
loops are transient three-stranded 
nucleic acid structures composed 
of a nascent RNA transcript 
hybridized with the DNA 
template strand and a single 
strand of displaced nontemplate 
DNA. The figure illustrates the 
physiological and dysfunctional 
consequences of their formation 
 
 
 
 
 
 
 
 
 
 
 
C9ORF72 
 
Among all of the genes causing ALS, a hexanucleotide repeat 
expansion (HRE) GGGGCC in the first intron of the 
C9ORF72 (C9) gene is the most common genetic cause of 
both familial and sporadic ALS and frontotemporal dementia 
(FTD) [41–43]. Less than 30 hexanucleotide repeats are gen- 
erally found in normal subjects, whereas up to thousands are 
detected in ALS patients [44]. 
The pathogenic mechanisms leading to the disease linked 
to C9 repeats expansion and how R-loop generation at the 
locus may be implicated are mostly unknown. However, dif- 
ferent mechanisms have been proposed. G-rich expansions in 
C9’s first intron can form G-quadruplexes in the displaced 
DNA strand (G4-DNA), which stabilizes the R-loops that 
form preferentially at G-rich sites. Additionally, C9 transcripts 
tend to form RNA G-quadruplexes (G4-RNA). Moreover, 
these G4-DNA sequences interfere with RNA polymerase II 
activity, causing premature interruption of transcription asso- 
ciated with the formation of truncated mRNAs [35, 45–48]. 
Haeusler et al. (2014) observed that R-loop resolution after 
RNase H treatment reduces the accumulation of abortive tran- 
scripts, suggesting that both of the secondary structures orig- 
inating from C9 HRE (G4-DNA and R-loops) contribute to 
the impairment of the transcriptional process. Afterwards, the 
truncated G4-transcripts tend to aggregate in the cellular nu- 
cleus and cytoplasm and bind to proteins. In particular, se- 
questration of the ribonucleoprotein nucleolin leads to its 
mislocalization as observed in motor neurons differentiated 
from C9 HRE ALS-induced pluripotent stem cells (iPSC), 
and nucleolar stress is detectable in the cerebral cortex tissue 
of affected patients [45]. 
There are many G/C combinations in addition to G4C2 
HRE of C9 that are responsible for R-loop formation and G4 
structures. To date, G4C2 repeat expansion has not been iden- 
tified in other genes known to cause ALS or FTD [49]. 
However, this does not mean that similar G/C combinations 
causing R-loop  formation and  G4 structures  would not be 
identified in the ∼ 50% of ALS cases for which we do not 
have a genetic explanation to date. On the other hand, C9 
HRE is associated with other neurological disorders, such as 
Alzheimer disease [43] and Huntington disease [50], suggest- 
ing a possible role of R-loops and G4 structures in these 
disorders. 
Although C9 HRE could explain the increase in R-loops in 
ALS patients’ cells, the role of R-loops in ALS pathogenesis is 
largely undetermined. A possible mechanism is related to the 
impairment of the transcription of the C9 gene, and this im- 
pairment may be related to R-loop formation. C9 expression is 
reduced in mutated C9 HRE cells, where the presence of re- 
pressive chromatin and hypermethylated regions on the C9 
gene has been observed [51–56]. Both of these events can 
cause reduced C9 expression. Multiple studies have suggested 
that also R-loops can negatively regulate transcription in vitro 
and in vivo through different mechanisms, including RNA 
polymerase pausing, antisense transcription, and histone 
methylation [57]. R-loop formation is also observed in 
unmethylated human CpG island promoters [58]. 
Transcription of C9 expansions is typically bidirectional, 
and the number of R-loops is increased in genes producing 
antisense RNA. Thus, the inhibition of C9 transcription could 
be explained by the bidirectional transcription/chromatin 
modification due to the presence of numerous R-loops [59]. 
However, the exact mechanism needs to be further investigat- 
ed. Recent data suggest that R-loops may not be necessary for 
the DNA hypermethylation linked with C9 HRE. In fact, 
preventing R-loop formation in neurons did not halt 
heterochromatinization of the HRE [60]. 
  
 
Walker and colleagues (2017) identified genomic instabil- 
ity driven by persistent accumulation of R-loops as a patho- 
logical mechanism of C9 HRE ALS [61]. They observed that 
overexpression of C9 expansions in human fibroblasts led to 
increases in R-loops and consequent DNA double-stranded 
breakages (DSBs). Insertion of 102 C9 repeats resulted in 
the formation of RNA foci but not dipeptide repeats (DPRs). 
This work describes an increase in R-loop formation induced 
by DPR expression, even though the mechanisms of this event 
are not known. However, they observed that R-loops were 
also formed in cells transfected with constructs that did result 
in the translation of DPRs 34 and 69, suggesting that different 
mechanisms mediate the formation of R-loops [61]. 
Remarkably, overexpression of senataxin, an RNA helicase 
that resolves R-loops, reduced the number of breakages and 
even inhibited DNA damage-mediated cell death. Together, 
these data support the notion that HRE leads to R-loop accu- 
mulation, which causes DNA damage and consequential cell 
death. The authors also identified a defect in the DNA repair 
capacity of the cells expressing C9 HRE due to defective 
signaling of the ataxia telangiectasia (ATM) protein, one of 
the principal DNA repair kinases, highlighting the relevance 
of genome instability in C9 pathogenesis [61]. Interestingly, 
the researchers also demonstrated R-loop accumulation, 
double-stranded breaks presence, and weak ATM activation 
in neurons from mice treated with viral vectors encoding for 
the repeat expansions and in postmortem spinal cord tissue 
from ALS patients. Finally, this study supports the notion that 
targeted modulation of R-loop homeostasis by R-loop- 
specific helicases, such as senataxin, or DSB repair kinetics 
by chromatin-modulating drugs may represent new therapeu- 
tic strategies for C9-associated diseases [61]. 
Overall, despite the possible illustrated explanations about 
R-loops and C9 connection, further research is still needed to 
clarify these topics. 
 
Ataxin-2 
 
The polyglutamine (polyQ) diseases are a group of neurode- 
generative disorders caused by expansion of the trinucleotide 
repeat cytosine-adenine-guanine (CAG), encoding a long 
polyQ tract in specific proteins. In particular, polyQ expansions 
in the ataxin-2 (ATXN-2) gene are associated with two different 
neurological diseases, ALS [11, 62] and spinocerebellar ataxia 
type 2 (SCA2) [63, 64]. Normally, ATXN2 contains 22 CAG 
repeats. Although significant expansions of CAG have been 
reported in SCA2, it has recently been demonstrated that 
intermediate-length repeats (27–33 repeats) might have a role 
in the pathogenesis of ALS [11, 62, 65]. 
Salvi et al. (2014) observed that Pbp1, the ortholog of 
ATXN2 in yeast, regulates R-loop generation by inhibiting 
deleterious R-loop formation at G4-DNA sites in the 
intergenic spacer regions of the ribosomal DNA repeats and 
at telomeres [66]. Through these actions, Pbp1 maintains ri- 
bosomal DNA stability [66]. In humans, ATXN2 might also 
inhibit R-loop formation at some loci although ATXN2 is 
mainly a cytoplasmic protein [11]. 
ATXN2 physically interacts with TAR DNA-binding pro- 
tein 43 (TDP-43) in a RNA-dependent manner, influencing 
the aggregation propensity of TDP-43. Reduction of ATXN2 
levels in TDP-43 ALS mice models results in a decrease in 
TDP-43 inclusions [67]. The strength of the ATXN2/TDP-43 
interaction is proportional to the length of the polyQ expan- 
sions [62]; thus, intermediate-length repeats could increase 
TDP-43 pathological modification. TDP-43 is one of the ma- 
jor disease-associated proteins in ALS and FTD [68]. Wild- 
type TDP-43 localizes in the nucleus, whereas mutated TDP- 
43 aggregates in the cytoplasm and is associated in neurons 
with stress granules and cytoplasmic aggregates containing 
translationally inert RNA and associated proteins that are 
markers of ALS [68, 69]. Other proteins accumulate in cyto- 
plasmic stress granules of degenerating neurons of ALS pa- 
tients, such as fused in sarcoma (FUS), a protein that plays an 
important role in ALS and FTD pathogenesis [65, 70]. Both 
TDP-43 and FUS bind to DNA and RNA and are associated 
with numerous nuclear and cytoplasmic steps of mRNA mat- 
uration and transport [24, 71]. After stress induction, ATNX2 
and TDP-43 both relocate to stress granules [25, 69] together 
with FUS [65]. Intermediate-length polyQ expansions in 
ATXN2 might be responsible for the sequestration of TDP- 
43 into cytoplasmic aggregates, altering its ability to bind 
DNA and RNA. Otherwise, mutated TDP-43 and FUS are 
potentially able to sequester ATXN2 into cytoplasmic stress 
granules, altering its possible function as a suppressor of R- 
loop formation [40]. It would be interesting to better under- 
stand the supposed role of ATXN2 in R-loop metabolism and 
to assess R-loop accumulation in SCA2 cells, particularly in 
those cells directly affected by the disease, such as human 
iPSCs-derived Purkinje cells. Moreover, studies of the direct 
function of TDP-43 and FUS in R-loop regulation in the nu- 
cleus might clarify the relationship between ATXN2 polyQ 
expansions and ALS. 
 
 
Senataxin 
 
Senataxin (SETX) is an RNA/DNA helicase that is mutated in 
two different neurological diseases, the recessive disorder 
ataxia with oculomotor apraxia type 2 (AOA2) [26] and a 
dominant juvenile form of amyotrophic lateral sclerosis 
(ALS4) [22] that has suggestive similarities with spinal mus- 
cular atrophy (SMA) and is characterized by the death of 
motor neurons in early childhood [22]. Identification of rare 
atypical forms of AOA2 and ALS4 that are also associated 
with SETX mutations enlarge the phenotypic spectrum that 
correlates with mutations in this gene [27, 72]. 
  
 
As for ATX2, the yeast homologous gene Sen1 was studied 
to understand SETX function and pathology. Sen1 has a role 
in the termination of transcription of noncoding RNAs and 
some mRNAs [23, 73] and the suppression of R-loop forma- 
tion and transcription-associated recombination [74]. These 
findings were confirmed also for SETX, which has a role in 
the resolution of R-loops typically formed at the transcription 
termination pause site in the human β-actin gene [16] and 
other genes via BRCA1-dependent activity [75]. SEXT/ 
BRCA1 recruitment to the 3′ pause site avoids the accumula- 
tion of R-loops that could induce DNA DSBs [75]. Both Sen1 
and SETX are responsible for the prevention of genome in- 
stability caused by R-loops via an unknown mechanism. This 
finding was also confirmed by the fact that in response to 
replication stress, SETX aggregates to form foci and 
relocalizes to R-loops with the RNA nuclear exosome, a 3′ 
to 5′ exoribonuclease complex that has a role in RNA quality 
control [76, 77]. SETX interaction with the exosome subunit 
Rrp45 [77] is dependent on SETX sumoylation, which is al- 
tered by AOA2 SETX mutations but not by ALS4 SETX mu- 
tations [77, 78]. Thus, it is possible that SETX unwinds RNA/ 
DNA hybrid structures at R-loop sites, whereas the nuclear 
exosome degrades the released RNAs that might rehybridize 
with portions of the DNA or exhibits some toxic effects. The 
reason why this action important in AOA2 pathogenesis and 
not in ALS4 pathogenesis remains unclear. 
Nevertheless, the role of R-loop formation itself in AOA2 
pathogenesis remains under investigation. To date, conflicting 
results are available in the literature. SETX knock out mice 
accumulate R-loops; however, in this context, R-loop accu- 
mulation does not lead to any phenotypic characteristics of 
AOA2 and otherwise causes male sterility [79, 80]. In fact, 
R-loops seem to increase in germ cells but not in neuronal 
cells in SETX, ATM (the gene causing ataxia teleangiectasia), 
TDP1 (responsible for spinocerebellar ataxia with axonal neu- 
ropathy 1), and APTX (that causes AOA1) knock out mice 
[80]. However, AOA2 cells exhibit a reduced telomeres length 
that could be explained by the role of SETX in telomere sta- 
bility given that R-loops and G4-DNA form at telomeres [28, 
29]. Indeed, accumulation of R-loops with non-coding RNA 
BTERRA^ at telomeric regions of DNA activates proteins 
involved in recombination [81]. 
Overall, these data could provide some evidence for AOA2 
pathogenesis but not for ALS4. 
The clinical similarities between ALS4 and SMA and the 
finding that SMN (the protein responsible for SMA pathogen- 
esis) recruits SETX to transcription termination sites [6] sug- 
gest a possible shared pathogenetic pathway involving R- 
loops between these two disorders. An R-loop pattern in 
ALS4 SETX-mutated cells was recently investigated by 
Grunseich and colleagues [82]. This team demonstrated that 
ALS4 patient cells with the heterozygous L389S SETX muta- 
tion have surprisingly less R-loops. The mechanism through 
which this mutation causes a decrease in the number of R- 
loops remains unclear. The authors suggest a possible SEXT 
gain of function connected with the mutation, which is con- 
sistent with the dominant pathway of transmission of SETX 
mutations in ALS4 [82]. Depletion of R-loops at gene pro- 
moters due to this SETX mutation affects gene expression. In 
particular, in ALS4 cells, low levels of R-loops reduce the 
expression of BAMBI, a negative regulator of transforming 
growth factor β (TGF-β) and consequently activate the 
TGF-β pathway through an increase in BAMBI promoter 
methylation. Genome-wide analyses identified greater than 
1200 gene promoters that are regulated in their methylation 
by R-loops, raising interesting questions regarding the possi- 
bility that R-loops could act as promoters of transcription [82]. 
The authors demonstrated that DNA methyltransferase 1 
(DNMT1) binds more avidly to double-stranded DNA than 
to RNA/DNA hybrids, explaining why genes with R-loops in 
their promoters are less methylated and consequently more 
transcribed. Therefore, R-loops could represent a mechanism 
by which nascent mRNAs promote their own transcription by 
blocking methylation-mediated gene silencing in a positive 
feedback loop [82]. Recently, Cohen and colleagues observed 
that SETX is recruited at DSBs that occur in transcriptionally 
active loci. Genome-wide mapping reveals that R-loops accu- 
mulate on the chromatin next to DSBs apart from small re- 
gions near DNA ends where they do not bind; these R-loop- 
free islands induced by the DSB itself are bound by SETX. 
SETX is not able to resolve DSBs alone but can facilitate 
genome stability and integrity by the recruitment of RAD 51 
that subsequently reduces the illegitimate rejoining of distant 
DNA ends and ensures cell vitality after DSBs [83]. These 
new functions of SETX could potentially play a role in 
AOA2/ALS4 neuropathies. 
Finally, there is evidence for a role of SETX in other human 
diseases, such as ovarian cancer, where SETX is deleted, sug- 
gesting a possible role as a tumor suppressor gene mediated 
through its R-loop-resolving function [84]. However, this hy- 
pothesis has not been confirmed by increased tumor suscepti- 
bility in AOA2 patients. 
 
RNA-Binding Proteins: TDP-43 and FUS this is subtitle no 
main title the stile is like Ataxin 2 
 
The RNA-binding proteins TAR DNA-binding protein 43 
(TDP-43) and fused in sarcoma (FUS) are both involved in 
the pathogenesis of familial and sporadic forms of ALS. These 
proteins can move between the nucleus and the cytoplasm and 
have important roles in RNA metabolism, such as transcrip- 
tion and mRNA splicing and transport. Moreover, in cases of 
cellular stress, these proteins can localize to stress granules, 
which are dynamic sites of translational repression [85, 86]. 
The presence of TDP-43 cytoplasmic ubiquitinated aggre- 
gates in the brain and spinal cord is a hallmark of ALS. FUS 
  
 
is occasionally found in TDP-43 aggregates or can form ag- 
gregates independently when it is mutated. Whether TDP-43 
and FUS aggregates and stress granules are the same cytoplas- 
mic structures and the exact composition and function of these 
aggregates remain unknown [87]. Cellular TDP-43 levels are 
under strict control. TDP-43 regulates its mRNA levels 
through a negative feedback loop [88]. Instead, TDP43 muta- 
tions at the C-terminal region increases its aggregation capa- 
bility and inhibits its self-regulation based on a negative feed- 
back mechanism [88]. 
In addition, FUS sequesters SMN in the cytoplasm, caus- 
ing alterations in snRNA levels and mRNAs splicing. Some of 
these alterations are responsible for SMN loss, creating a vi- 
cious circle [30]. Moreover, when overexpressed, SMN in- 
duces stress granules assembly [31]. As previously explained, 
ATXN2 interacts with FUS, TDP43, and other RNA-binding 
proteins and localizes within stress granules [40]. As noted, 
these protein alterations are various and variably interconnect- 
ed. One potential model to explain all of these interconnec- 
tions among different genetic defects is a self-reinforcing loop 
that gains strength with disease progression in which stress 
granules or cytoplasmic protein aggregates cause the seques- 
tration of proteins normally located in the nucleus, such as 
TDP-43, ATXN2, and SMN, altering their nuclear functions, 
in particular their roles in RNA splicing, processing, and trans- 
port as well as R-loop metabolism and resolution. R loop 
accumulation can subsequently lead to genomic instability 
and accumulation of mutations that can promote stress gran- 
ules formation, maintaining the cycle [40]. In support of this 
model, the implications of FUS and TDP-43 in the prevention 
of R-loop-associated DNA damage has been recently pro- 
posed in ALS models [89]. 
All of these findings and hypotheses lead to numerous 
other questions. Overall, we reported that alterations in splic- 
ing factors, transport proteins, and molecules implicated in 
RNA processing caused by their aggregation in cytoplasm 
or by genetic mutations subsequently promote DNA double- 
strand breaks via R-loop accumulation. This finding reveals 
the genetic instability that causes motor neuron death in both 
SMA and ALS. However, why selective death of motor neu- 
rons occurs given that these mutations are located in ubiqui- 
tously expressed genes is a very perplexing and problematic 
question. The sensitivity of this cell type to genomic instabil- 
ity due to an inefficient repair machinery is a possible hypoth- 
esis; however, this hypothesis could be incorrect or could 
represent only one explanation [90]. 
 
Spinal Muscular Atrophy 
 
Spinal muscular atrophies (SMAs) are a group of hereditary 
diseases affecting lower motor neurons that manifest clinically 
with progressive proximal paralysis, muscular atrophy, respi- 
ratory distress, and death by the age of 2 years in the most 
aggressive forms of the disease [91]. Today, the term SMA is 
used commonly to denote 5q SMA or Bproximal spinal mus- 
cular atrophy^, the most frequent form of the disease, account- 
ing for approximately 95% of all SMAs [91]. In fact, 5q SMA 
is the most common monogenic cause of infant mortality due 
to mutations or deletions of the survival of motor neuron 1 
(SMN1) gene located on chromosome 5q13 and results in the 
subsequent reduction of SMN protein expression. Its inheri- 
tance pattern is autosomal recessive [91]. 
Recent advances in understanding SMA pathogenesis have 
laid the foundation for new therapeutic approaches. The first 
drug approved for all types of SMA was nusinersen, a modi- 
fied antisense oligonucleotide (ASO) that modulates the splic- 
ing of SMN2 mRNA transcripts [92]. Moreover, other strate- 
gies have been proposed, including gene therapy using adeno- 
associated virus (AAV) vectors carrying the SMN gene with 
positive results obtained in the first clinical trial, modulation 
of SMN2 transcripts, neuroprotection, and targeting of numer- 
ous peripheral targets (such as skeletal muscles) [92]. 
The second most frequent form of SMA is spinal muscular 
atrophy with respiratory distress (SMARD1), a rare and fatal 
disease that typically affects children during the first few 
months of life. SMARD1 is caused by autosomal recessive 
inherited mutations in the IGHMBP2 gene, which encodes the 
immunoglobulin μ-binding protein 2. Mutations in this gene 
leads to motor neuron degeneration that primarily manifests 
with muscular atrophy and diaphragmatic palsy, requiring 
prompt and permanent ventilation; without ventilation, the 
disease is fatal in few years [93, 94]. Currently, no approved 
treatment is available to date, but different therapeutic strate- 
gies, such as gene therapy or stem cell transplantation, have 
exhibited positive results in nmd mice [93, 94]. 
 
SMA 5q 
 
SMN is a ubiquitously expressed protein, and its reduction 
causes selective motor neuron death in SMA. Its functions 
are numerous, but it seems to exert a critical role in RNA 
splicing processes [91]. 
R-loop dynamics can be regulated by splicing factors [12]. 
Indeed, impaired mRNA splicing driven by loss of 
spliceosomal components promotes R-loop accumulation 
and DNA DSBs in neurons in a zebrafish model. Resolution 
of R-loops after RNase H1 overexpression rescued DNA 
damage and neuronal apoptosis in zebrafish splicing factor 
mutants [95]. The widespread splicing alterations that are in- 
duced by reductions in SMN protein levels in SMA are po- 
tentially associated with impaired formation of transcriptional 
R-loops and subsequent global DNA damage and stress re- 
sponses, which could ultimately compromise motor neurons 
survival. 
In splicing pathways, SMN plays a key role in the assembly 
of the spliceosomal small nuclear ribonucleoproteins 
  
 
(snRNPs) that are necessary for intron removal during 
premRNA splicing [96, 97]. Jangi et al. (2017) observed that 
human SMN1-silenced SH-SY5Y cells accumulate R-loops 
and DNA DSBs in vitro mainly over retained introns [90]. 
Intron retention is defined by the presence of a transcript- 
confirmed intron within a transcript-confirmed exon. 
Interestingly, retained introns are not though to alter transcrip- 
tion but only generate cellular stress. Indeed, in an SMA 
mouse model, SMN-dependent retained introns did not signif- 
icantly affect the expression of the genes in which they were 
located, suggesting that these introns are ultimately removed 
in the nucleus, probably more slowly than that noted in normal 
cells. This notion could explain why retained introns do not 
affect translation but could be sufficient to trigger cellular 
stress. These observations highlight the greater importance 
of the process of stochastic intron retention than the specific 
identity of retained introns [90]. 
Pervasive intron retention was also observed in SMN- 
depleted human SH-SY5Y neuroblastoma cells and SMA- 
induced pluripotent stem cell (iPSC)-derived motor neurons 
in association with p53 pathway activation and increases in γ- 
H2A.X and other markers of DNA damage response [90]. The 
mechanism connecting the reduction in SMN and DNA insta- 
bility remains unclear. The authors proposed a role for R- 
loops. In fact, they demonstrated that introns frequently 
retained after SMN depletion in SH-SY5Y cells were enriched 
in R compared with spliced introns. They also demonstrated 
that these retained introns were rich in GC nucleotides that 
represent valid substrates for R-loop formation [90]. 
Moreover, resolution of R-loops through RNase H1 overex- 
pression rescued DSBs in SH-SY5Y cells depleted of SMN. 
Low SMN levels subsequently induce defects in intron re- 
moval and R-loop formation, causing genome instability. 
The mechanism by which this action leads to specific motor 
neurons death remains undefined. However, the extent of in- 
tron retention and R-loop accumulation is probably dependent 
on SMN expression levels, and this information could be im- 
portant in intermediate models of SMA (SMA type II and 
SMA type III) [90]. 
SMN may also have an active role in R-loop resolution 
through the recruitment of senataxin [6]. RNA polymerase 
II, senataxin, and SMN are involved in a pathway for R-loop 
resolution that could possibly have a role in the pathogenesis 
of neurodegenerative disorders when altered. 
 
Spinal Muscular Atrophy with Respiratory Distress 1 
 
The protein IGHMBP2, the loss of which causes SMARD1, 
was initially described as related to R-loop-dependent class- 
switch recombination [98]. Given the homologies in its se- 
quence, IGHMBP2 is considered a member of the helicase 
superfamily 1, and its biochemical characterization suggests 
ATP-dependent 5′ → 3′ DNA/RNA helicase activity [98]. The 
majority of the pathogenic mutations in SMARD1 patients are 
located in the helicase domain of IGHMBP2 [99, 100]. This 
information together with the similarity with the protein 
SETX suggests a probable link between IGHMBP2 defects 
and abnormal R-loop formation that should be investigated in 
the context of SMARD1. 
 
 
R-L oop Therapies 
 
R-loops are becoming increasingly interesting in the patho- 
genesis of neurodegenerative diseases and in the development 
of therapies to treat these conditions. If SMA and ALS share 
the pathogenic pathway of DNA damage induction driven by 
R-loops and consequent cellular death, then R-loop manipu- 
lation strategies would have important implications, including 
a possible therapeutic target role in multiple disorders. 
Therefore, it could be interesting to further investigate the R- 
loop-related pathogenesis of rare neurodegenerative disorders, 
such as SMARD1 and ALS4. The conspicuous number of 
alterations in RNA metabolism identified in different neuro- 
muscular diseases raises the hypothesis of a common defect 
underling this spectrum of illnesses. This potentially common 
defect could provide possible therapeutic strategies not only 
for rare diseases but also other neurodegenerative disorders on 
this spectrum. R-loops also warrant investigation as therapeu- 
tic targets for diseases, such as SMA, that already have an 
available approved therapy. R-loop-based therapies could in- 
deed provide additional benefits to SMA patients beyond the 
therapeutic effect of SMN restoration alone. However, despite 
their apparent importance in different pathogenic pathways, 
R-loops have yet to be fully exploited in drug design [57]. 
Numerous different compounds can bind to DNA/RNA 
hybrids, such as the aminoglycosides paramomycin and neo- 
mycin, the polyamides netropsin and distamycin, and ethidium 
bromide. These compounds intercalate into the hybrids and 
bind to the nucleic acid strands [101]. Despite their sensitivity 
to DNA/RNA hybrids, these compounds also recognize 
dsDNAs and RNAs, causing these agents to be mutagenic 
and potentially dangerous. This toxicity limits their application 
in clinical therapeutic strategies. However, recent studies dem- 
onstrated that a combination of these compounds, such as a 
combination of ethidium bromide derivatives and aminogly- 
cosides, could bind more specifically to DNA/RNA hybrids, 
permitting the use of a subnanomolar dosage and providing a 
powerful tool for future R-loop-based therapy [101]. 
As an alternative, it is possible to influence R-loops by 
targeting some of the pathological mechanisms that favor their 
formation. For example, R-loops in trinucleotide repeat ex- 
pansions could be modulated by targeting the expansions 
themselves [102]. Colak et al. (2014) demonstrated that a 
small molecule can inhibit R-loop generation at CGG repeats 
expansion in the FMR1 gene, preventing FMR1 silencing in 
  
 
fragile X syndrome (FXS) [103]. In C9ORF72 HRE patholo- 
gy, resolving the quadruplex structures responsible for the 
stabilization of R-loops may represent a possible strategy to 
prevent the pathogenetic consequences of R-loops. 
R-loop levels can also be modulated by targeting proteins 
physiologically involved in their metabolism. Upregulation of 
genes encoding R-loop-specific helicases, such as senataxin, 
demonstrated that DNA/RNA helicase activity is responsible 
for R-loop resolution at transcription termination sites [22, 
32], potentially representing a promising strategy to treat pa- 
thology characterized by R-loop accumulation as noted in 
C9ORF72-associated diseases [61]. Similarly, modulation of 
ataxin could represent another therapeutic possibility. Ataxin 
was suggested as a possible R-loop regulator and is involved 
in numerous pathways related to R-loops, such as TDP-43 and 
FUS stress response pathway [67]. Overexpression of endo- 
nuclease RNase H1/H2 that specifically degrades RNA of 
RNA/DNA hybrids could represent another strategy to reduce 
R-loop levels and consequently ameliorate DNA damage, as 
observed in SH-SY5Y cells depleted of SMN [90]. Increases 
in the R-loop-resolving activity of these enzymes with specific 
ligands could be important for R-loop-related pathology. 
Finally, an alternative approach is to target the downstream 
effect of R-loops promoting DSB repair kinetics with 
chromatin-modulating drugs [61]. 
The possibility of targeting R-loops in different human dis- 
eases is exciting. It is important to remember that R-loops are 
ubiquitously distributed and are involved in different physio- 
logical processes to ensure that future treatments will be spe- 
cific for pathologic mechanisms [57]. 
 
 
Conclusion and Perspectives 
 
R-loops are becoming central molecular players in different 
neurological disorders and are deserving of increased attention 
in pathogenic theories and therapeutic strategies. R-loops 
form ubiquitously in different conditions and in different or- 
ganisms and are necessary for main biological processes. 
However, R-loops can also be deleterious to cells, promoting 
DNA damage and genome instability. Distinguishing Bbad R- 
loops^ from Bgood R-loops^ is fundamental in R-loop-based 
therapeutic research given that we do not know whether up- 
regulation of R-loop modulators, such as senataxin, or admin- 
istration of R-loop-resolving compounds could discriminate 
between these two forms. 
There are two major issues in R-loop pathways: (1) How 
do distinct mutations in disease-related genes induce aberrant 
R loop formation? and (2) What are the consequences that 
lead to the different pathologies? In both cases, many pieces 
are missing; thus, we lack a full comprehension of R-loop- 
related diseases. However, some themes should be considered 
certainties. First, R-loop dysregulation is clearly connected 
with DNA damage, the consequences of which vary from 
cellular death to neurodegeneration. Second, R-loops have 
an active role in transcription regulation both locally and glob- 
ally that contributes in particular to the pathogenesis of expan- 
sion diseases. Both of these pathological themes likely occur 
together in the same pathology, and other mechanisms are also 
likely involved. 
Moreover, defining the roles of R-loops in motor neuron 
biology will be fundamental to understanding the selectivity 
of motor neuron death in neurodegenerative disorders. Indeed, 
Sorrels et al. (2018) demonstrated that control of R-loop levels 
in neuronal cells during embryogenesis is crucial for the de- 
velopment of the central nervous system [95]. This informa- 
tion opens the possibility that R-loop-related motor neuron 
diseases have their pathogenic roots in early central nervous 
system development, which clearly could change many per- 
spectives on these disorders. 
In the future, studying R-loops in other human diseases will 
be relevant. This information will shed some light on R-loop 
pathways and could represent a step forward in the under- 
standing of human diseases and our ability to treat them. 
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